Annalisa Mondi

Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study

Mattia Prosperi, Massimiliano Fabbiani, Iuri Fanti et al. · BMC Infectious Diseases · 2012 · 90 citations · Full text

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)

Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quirós-Roldán et al. · Journal of Antimicrobial Chemotherapy · 2016 · 75 citations · Full text

Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons

Margalida Rotger, Tracy R. Glass, Thomas Junier et al. · Clinical Infectious Diseases · 2013 · 73 citations · Full text

Effect of local and remote ischemic preconditioning on endothelial function in young people and healthy or hypertensive elderly people

Leo Moro, Claudio Pedone, Annalisa Mondi et al. · Atherosclerosis · 2011 · 56 citations

Thrombosis, Hypertension, Young People +12

Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)

Simona Di Giambenedetto, Massimiliano Fabbiani, Manuela Colafigli et al. · Journal of Antimicrobial Chemotherapy · 2013 · 52 citations